Application error: a client-side exception has occurred (see the browser console for more information).

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

To close out Men’s Health Month, the Cancer Connections team sat down with Dr. William Dahut, the American Cancer Society’s ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Scientists have revealed how certain immune cells may be quietly helping prostate cancer grow—and how blocking them could help the body fight back.

Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Andrea Miyahira speaks with Emily Grist about a STAMPEDE biomarker analysis examining treatment selection for advanced prostate cancer. Using data from over 3,900 patients with transcriptome-wide ...